WorkBoat Header Background Image

WorkBoat+ Membership – Free to Join

Thank you for another great WorkBoat Show! We hope to see everyone back in New Orleans December 2–4, 2026. Save the date!

Workboat Indexes

Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Workboat Indexes
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

52.04 -0.52 (-1.00%)
Streaming Delayed Price Updated: 9:46 AM EST, Dec 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
98 99 Next >
News headline image
This Smallcap Pharma Stock Is Gaining Retail Buzz Ahead Of A Key FDA Ruling ↗
The FDA is expected to issue a decision on Vanda’s Tradipitant, a motion-sickness treatment aimed at preventing vomiting, on Dec. 30, 2025. 
Via Stocktwits
News headline image
Buying This Pharmaceutical Stock Could Make You a Millionaire Retiree ↗
A key product portfolio is bringing in blockbuster revenue. 
Via The Motley Fool
News headline image
Betting on the 'Santa Squeeze': Unusual Options Activity Surges as 2025 Draws to a Close
As the sun sets on 2025, the U.S. stock market is not entering the quiet holiday lull typical of decades past. Instead, a massive surge in "unusual options activity" is signaling a high-stakes... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
Novo Nordisk, Trinity Biotech, Starfighters Space, VisionWave, ServiceNow: Stocks Making The Biggest Moves Today ↗
Via Stocktwits
Novo Nordisk’s Worst Year In Over Four Decades May Be Ending — Thanks To A Weight-Loss Pill ↗
Via Stocktwits
News headline image
Is Eli Lilly Pulling Ahead in the Weight Loss Drug Battle? ↗
It's a two-horse race right now, sort of. 
Via The Motley Fool
News headline image
Pfizer’s 2026 Outlook Misses the Mark as Post-Pandemic Hangover and Patent Cliff Loom
NEW YORK — On December 16, 2025, Pfizer (NYSE:PFE) issued a conservative financial outlook for the 2026 fiscal year, falling short of Wall Street’s expectations and signaling a prolonged period of... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
The Oral Revolution: Novo Nordisk’s High-Stakes Bet on the Wegovy Pill
Introduction As of December 25, 2025, the global pharmaceutical landscape is witnessing a seismic shift centered on a single Danish company: Novo Nordisk (NYSE: NVO). Long the undisputed king of the... 
Via PredictStreet
Topics Economy Intellectual Property World Trade
News headline image
The Trillion-Dollar Pharma: A Deep Dive into Eli Lilly’s (LLY) Dominance in the Weight-Loss Era
As of December 25, 2025, the global pharmaceutical landscape has been fundamentally reshaped by a single entity: Eli Lilly and Company (NYSE: LLY). In a year defined by breakthrough medical treatments... 
Via PredictStreet
Topics Economy Government Intellectual Property
News headline image
The Weight of Innovation: Eli Lilly’s Dominance in the GLP-1 Era
Date: December 24, 2025By: Financial Research Insights Introduction As 2025 draws to a close, few companies have dominated the financial and medical headlines as consistently as Eli Lilly and Company... 
Via PredictStreet
Topics Economy
News headline image
Novo Nordisk (NVO) Research: The Oral Wegovy Pivot and the 2026 Outlook
As of December 24, 2025, the pharmaceutical landscape is witnessing a pivotal shift in the treatment of chronic obesity. Novo Nordisk (NYSE: NVO), the Danish titan that pioneered the GLP-1 revolution,... 
Via PredictStreet
Topics Economy Intellectual Property
News headline image
Hims & Hers Hit A GLP-1 Speed Bump This Year — But Growth Is Just Cooling, Not Cracking ↗
Hims & Hers has drawn scrutiny for selling compounded GLP-1 treatments – lower-cost, unapproved alternatives to blockbuster weight-loss drugs made by Eli Lilly and Novo Nordisk. 
Via Stocktwits
News headline image
Novo Nordisk A/S-Spons ADR (NYSE:NVO): A Prime Candidate for Steady Dividend Income ↗
Novo Nordisk (NVO) exemplifies a strong dividend stock with a 3.83% yield, a history of increases, and robust profitability for sustainable passive income. 
Via Chartmill
News headline image
Stock Market Today, Dec. 23: U.S. Stocks Hold Near Records on Narrow Tech-Led Gains ↗
Mega-cap tech and AI stocks carried major indexes in thin holiday trading, while healthcare strength after Novo Nordisk’s Wegovy pill approval added selective support amid a resilient economic... 
Via The Motley Fool
Topics Artificial Intelligence Economy Stocks
News headline image
Why Novo Nordisk Stock Popped Today ↗
The biotech titan's Wegovy pill is coming to the massive U.S. weight loss market. 
Via The Motley Fool
News headline image
Novo Nordisk Stock Soars as "Wegovy Pill" Gains FDA Approval, Reshaping Obesity Market
Shares of Novo Nordisk (NYSE: NVO) surged more than 8% in early trading on December 23, 2025, after the pharmaceutical giant secured a landmark FDA approval for its high-dose oral semaglutide, branded... 
Via MarketMinute
News headline image
Stock Market Today, Dec. 23: Novo Nordisk Surges After FDA Approves Oral Wegovy Weight Loss Pill ↗
On Dec. 23, 2025, investors weighed a newly approved oral obesity pill’s first-mover edge and its ripple effects across healthcare. 
Via The Motley Fool
Topics Stocks
News headline image
Novo Nordisk Breaks the Mold: Oral Obesity Breakthrough Sends Shares to New Heights as Pharma Landscape Shifts
BAGSVAERD, Denmark — In a landmark decision that has sent shockwaves through the global pharmaceutical industry, Novo Nordisk (NYSE:NVO) has secured U.S. Food and Drug Administration (FDA) approval for... 
Via MarketMinute
Topics Economy
News headline image
Which stocks are most active on Tuesday? ↗
Curious about the most active stocks on Tuesday? Find out which stocks are dominating the market action! 
Via Chartmill
News headline image
Thin Trading and High Hopes: Markets Eye a 'Santa Claus Rally' as 2025 Draws to a Close
As the sun sets on a volatile but ultimately record-breaking year, Wall Street has entered its final, holiday-shortened trading week of 2025. With the S&P 500 sitting at a historic peak of 6,904 as of... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Santa Claus Rally Solidifies as S&P 500 Secures Third Consecutive Winning Session Amid Economic Resilience
The U.S. equity markets continued their year-end ascent on Tuesday, December 23, 2025, as the S&P 500 (INDEXSP:.INX) notched its third consecutive winning session. This momentum, often referred to as... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
These stocks are gapping in today's session ↗
The market is buzzing with gapping stocks on Tuesday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
News headline image
The Great Biotech Rebound: How Pricing Clarity Rescued the Drug Sector in 2025
After a tumultuous first half of 2025 that saw the pharmaceutical and biotechnology sectors languish under a cloud of regulatory dread, the industry is ending the year on a surprisingly high note. The... 
Via MarketMinute
Topics Economy
Nasdaq, S&P 500 Futures Tread Caution Ahead Of GDP, Confidence Data: Why NVO, ZIM, SIDU Are On Traders' Radar Today ↗
Via Stocktwits
Topics Stocks
News headline image
Novo Nordisk Stock Soars After Hours As FDA Greenlights Wegovy Pill For Weight Loss ↗
The Danish drugmaker expects to launch the pill in the U.S. in January. 
Via Stocktwits
News headline image
The Incretin Empire: Eli Lilly’s (LLY) Path to a $1 Trillion Market Cap and Beyond
As of December 22, 2025, the global equity markets are witnessing a historic recalibration of the healthcare sector. For decades, the "Trillion Dollar Club" was an exclusive enclave for Silicon... 
Via PredictStreet
Topics Economy Intellectual Property
News headline image
The Pfizer Pivot: A Deep-Dive into PFE’s 2025 Financial Recovery and Strategic Rebirth
As of today, December 22, 2025, Pfizer Inc. (NYSE: PFE) stands as a case study in corporate reinvention and the brutal reality of the post-pandemic "hangover." Once the darling of the global healthcare... 
Via PredictStreet
Topics Economy Intellectual Property
News headline image
Should You Forget Novo Nordisk and Buy This Magnificent High-Yield Drug Stock Instead? ↗
Novo Nordisk gained a head start in the GLP-1 race but then fell behind; Pfizer is working hard to catch up to the new leader. 
Via The Motley Fool
News headline image
Novo Nordisk (NYSE:NVO) Identified as a 'Decent Value' Stock with Strong Fundamentals ↗
Novo Nordisk (NVO) presents a value opportunity, trading at a discount to peers with top-tier profitability and solid financial health. 
Via Chartmill
News headline image
2026 Market Outlook: Key Themes and Predictions
As the final weeks of 2025 draw to a close, the global financial landscape is entering a pivotal transformation. The "AI Gold Rush" that defined the previous two years is evolving from a speculative... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
< Previous 1 2 3 4 5 6 7 8 9
...
98 99 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Privacy Policy DSAR Requests Terms of Use Locations Events, Products & Services
© 2025 Diversified Communications. All rights reserved.